Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H19N3O4S.3H2O |
Molecular Weight | 403.451 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=CC=C3)C(O)=O
InChI
InChIKey=RXDALBZNGVATNY-CWLIKTDRSA-N
InChI=1S/C16H19N3O4S.3H2O/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8;;;/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23);3*1H2/t9-,10-,11+,14-;;;/m1.../s1
Molecular Formula | C16H19N3O4S |
Molecular Weight | 349.405 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Ampicillin is a penicillin beta-lactam antibiotic. The following gram-negative and gram-positive bacteria have been shown in in vitro studies to be susceptible to ampicillin: Hemolytic and nonhemolytic streptococci, Streptococcus pneumoniae, Nonpenicillinase-producing staphylococci, Clostridium spp., B. anthracis, Listeria monocytogenes, most strains of enterococci, H. influenzae, N. gonorrhoeae, N. meningitidis, Proteus mirabilis, many strains of Salmonella, Shigella, and E. coli. Ampicillin is indicated in the treatment of bacterial meningitis, septicemia, endocarditis, urinary tract, gastrointestinal, respiratory tract infections caused by susceptible strains of the designated organisms.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | AMPICILLIN SODIUM Approved UseAmpicillin is indicated in the treatment of bacterial meningitis, septicemia, endocarditis, urinary tract, gastrointestinal, respiratory tracti nfections caused by susceptible strains of bacteria (Hemolytic and nonhemolytic streptococci, Streptococcus pneumoniae, Nonpenicillinase-producing staphylococci, Clostridium spp., B. anthracis, Listeria monocytogenes, most strains of enterococci, H. influenzae, N. gonorrhoeae, N. meningitidis, Proteus mirabilis, many strains of Salmonella, Shigella, and E. coli.) |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
129.5 μg/mL |
2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered: SULBACTAM |
AMPICILLIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
15.04 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
58.74 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1 h |
2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered: SULBACTAM |
AMPICILLIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
72% |
AMPICILLIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
650 mg 3 times / day multiple, intravenous (mean) Studied dose Dose: 650 mg, 3 times / day Route: intravenous Route: multiple Dose: 650 mg, 3 times / day Co-administed with:: Sulbactam(300-350 mg; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
unhealthy, 11 to 18 months n = 4 Health Status: unhealthy Condition: acute pyelonephritis Age Group: 11 to 18 months Sex: M+F Population Size: 4 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
Disc. AE: Skin rash... AEs leading to discontinuation/dose reduction: Skin rash (25%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
5 g 3 times / day multiple, intravenous Highest studied dose Dose: 5 g, 3 times / day Route: intravenous Route: multiple Dose: 5 g, 3 times / day Co-administed with:: Sulbactam(500 mg; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.161 |
unhealthy, adult n = 9 Health Status: unhealthy Condition: Bacterial infections Age Group: adult Sex: M+F Population Size: 9 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.161 |
Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.161 |
0.5 g 1 times / day single, intramuscular Recommended Dose: 0.5 g, 1 times / day Route: intramuscular Route: single Dose: 0.5 g, 1 times / day Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
Other AEs: Injection site pain... Other AEs: Injection site pain Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Co-administed with:: Sulbactam(0.5 g; single dose) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
healthy, adult n = 11 Health Status: healthy Age Group: adult Sex: M Population Size: 11 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
Other AEs: Injection site pain, Creatine phosphokinase increased... Other AEs: Injection site pain (grade 3-4, 100%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40Creatine phosphokinase increased (100%) |
2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Other AEs: Injection site pain, Rash... Other AEs: Injection site pain (1%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160Rash (1%) Diarrhea (5%) Fatigue (3%) Chills (1%) Headache (1%) AST increased (3%) Bilirubin increased (1%) Creatinine increased (1%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Other AEs: Chest pain, Flatulence... Other AEs: Chest pain (5%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53Flatulence (5%) Diarrhea (10%) Injection site pain (5%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Other AEs: Injection site pain, Phlebitis... Other AEs: Injection site pain (0.8%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57Phlebitis (5.3%) Chest pain (0.8%) Diarrhea (6.8%) Vomiting (0.8%) Retention of urine (0.8%) Rash (0.8%) Epistaxis (0.8%) Edema (0.8%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Other AEs: Thrombophlebitis, Nausea... Other AEs: Thrombophlebitis (6.7%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155Nausea (6.7%) Diarrhea (6.7%) Rash (6.7%) Blood eosinophils increased (6.7%) AST increased (6.7%) ALT increased (13.3%) GGT increased (13.3%) Alkaline phosphatase increased (6.7%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Skin rash | 25% Disc. AE |
650 mg 3 times / day multiple, intravenous (mean) Studied dose Dose: 650 mg, 3 times / day Route: intravenous Route: multiple Dose: 650 mg, 3 times / day Co-administed with:: Sulbactam(300-350 mg; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
unhealthy, 11 to 18 months n = 4 Health Status: unhealthy Condition: acute pyelonephritis Age Group: 11 to 18 months Sex: M+F Population Size: 4 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
Injection site pain | 0.5 g 1 times / day single, intramuscular Recommended Dose: 0.5 g, 1 times / day Route: intramuscular Route: single Dose: 0.5 g, 1 times / day Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
|
Creatine phosphokinase increased | 100% | 1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Co-administed with:: Sulbactam(0.5 g; single dose) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
healthy, adult n = 11 Health Status: healthy Age Group: adult Sex: M Population Size: 11 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
Injection site pain | grade 3-4, 100% | 1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Co-administed with:: Sulbactam(0.5 g; single dose) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
healthy, adult n = 11 Health Status: healthy Age Group: adult Sex: M Population Size: 11 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
Bilirubin increased | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Chills | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Creatinine increased | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Headache | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Injection site pain | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Rash | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
AST increased | 3% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Fatigue | 3% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Diarrhea | 5% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Diarrhea | 10% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Chest pain | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Flatulence | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Injection site pain | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Chest pain | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Edema | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Epistaxis | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Injection site pain | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Rash | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Retention of urine | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Vomiting | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Phlebitis | 5.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Diarrhea | 6.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
ALT increased | 13.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
GGT increased | 13.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
AST increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Alkaline phosphatase increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Blood eosinophils increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Diarrhea | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Nausea | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Rash | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Thrombophlebitis | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 2.0 |
yes [Inhibition 1000 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
Ampicillin-resistant enterococci in a Swedish university hospital: nosocomial spread and risk factors for infection. | 2001 |
|
Superantigen antagonist peptides. | 2001 |
|
Antibiotic susceptibility, serum response and surface properties of Klebsiella species. | 2001 |
|
Survey of transcripts in the adult Drosophila brain. | 2001 |
|
The frequency of silencing in Arabidopsis thaliana varies highly between progeny of siblings and can be influenced by environmental factors. | 2001 |
|
Effectiveness of specific RNA-mediated interference through ingested double-stranded RNA in Caenorhabditis elegans. | 2001 |
|
Enterobacter spp. infections complicating the course of HIV disease. | 2001 Apr |
|
Prevalence of penicillin-resistant Streptococcus pneumoniae in Kuwait. | 2001 Apr |
|
Antimicrobial resistance of Streptococcus pneumoniae at a university hospital in Saudi Arabia. | 2001 Apr |
|
Antibiotic use and development of resistance in blood culture isolates: 8 years of experience from a cancer referral center. | 2001 Apr |
|
The isolation and characterization of Campylobacter jejuni subsp. jejuni from domestic geese (Anser anser). | 2001 Apr |
|
Antibiotic resistance among Listeria, including Listeria monocytogenes, in retail foods. | 2001 Apr |
|
[Beta-lactam and macrolide resistance in Streptococcus pneumoniae]. | 2001 Apr |
|
[Vancomycin-resistant enterococci(VRE)]. | 2001 Apr |
|
Use of antibiotics to treat bacteriuria of pregnancy in the Nordic countries. Which antibiotics are appropriate to treat bacteriuria of pregnancy? | 2001 Apr |
|
Serogroups and antimicrobial susceptibility of non-typhoidal salmonellas in children. | 2001 Feb |
|
Enterococcus faecalis resistant to vancomycin and teicoplanin (VanA phenotype) isolated from a bone marrow transplanted patient in Brazil. | 2001 Feb |
|
Spectrophotometric determination of ampicillin, dicluxacillin, flucloxacillin and amoxicillin antibiotic drugs: ion-pair formation with molybdenum and thiocyanate. | 2001 Feb |
|
Vibrio parahaemolyticus associated with cholera-like diarrhea among patients in North Jakarta, Indonesia. | 2001 Feb |
|
An unusual blood culture isolate in a 15-year-old boy. | 2001 Feb |
|
[Streptococcus gallolyticus infections in racing pigeons, a literature review]. | 2001 Feb 1 |
|
Clostridium difficile--Associated diarrhea: A review. | 2001 Feb 26 |
|
Shigella and Salmonella strains isolated from children under 5 years in Gaborone, Botswana, and their antibiotic susceptibility patterns. | 2001 Jan |
|
Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria. | 2001 Jan |
|
Salmonella typhimurium-endocarditis secondary to an acquired environmental infection: a case report. | 2001 Jan |
|
Effect of single-dose prophylactic ampicillin and sulbactam on wound infection after tension-free inguinal hernia repair with polypropylene mesh: the randomized, double-blind, prospective trial. | 2001 Jan |
|
The plasmid pcDNA3 differentially induces production of interferon-alpha and interleukin-6 in cultures of porcine leukocytes. | 2001 Jan 10 |
|
A suicide-substrate mechanism for hydrolysis of beta-lactams by an anti-idiotypic catalytic antibody. | 2001 Jan 26 |
|
[Prevalence of Moraxella catarrhalis colonization in asymptomatic carriers under 6 years of age]. | 2001 Jan-Feb |
|
[Immunocorrecting and protective effect of proteolytic enzymes on antibody formation in mice in staphylococcal infection and antibiotic treatment]. | 2001 Jan-Feb |
|
Acinetobacter infections in patients with human immunodeficiency virus infection: microbiological and clinical epidemiology. | 2001 Jan-Feb |
|
Highly efficient synthesis of ampicillin in an "aqueous solution-precipitate" system: repetitive addition of substrates in a semicontinuous process. | 2001 Jun 5 |
|
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998. | 2001 Mar |
|
Standard case management of pneumonia in hospitalized children in Uruguay, 1997 to 1998. | 2001 Mar |
|
Longitudinal surveillance of antibiotic use in the hospital. | 2001 Mar |
|
Improved agar diffusion method for detecting residual antimicrobial agents. | 2001 Mar |
|
Factors associated with antibiotic resistance in coliform organisms from community urinary tract infection in Wales. | 2001 Mar |
|
Serogroups and antimicrobial susceptibility among Escherichia coli isolated from farmed mink (Mustela vison Schreiber) in Denmark. | 2001 Mar 20 |
|
Emergence of vancomycin-resistant enterococci. | 2001 Mar-Apr |
|
Association between antibiotic resistance and the expression of Dr adhesin among uropathogenic Escherichia coli. | 2001 Mar-Apr |
|
Ureidopenicillins and risk of Clostridium difficile infection. | 2001 May |
|
Carriage of antibiotic-resistant bacteria by healthy children. | 2001 May |
|
Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome. | 2001 May |
|
Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. | 2001 May 15 |
|
Ampicillin-resistant Escherichia coli in gestational pyelonephritis: increased occurrence and association with the colonization factor Dr adhesin. | 2001 May 15 |
|
Treatment of foodborne listeriosis. | 2001 May 15 |
|
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center. | 2001 Spring |
|
In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification. | 2001 Spring |
|
A multicenter study of the antimicrobial susceptibility of Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis isolated from patients with community-acquired lower respiratory tract infections in 1999 in Portugal. | 2001 Spring |
|
Variation in clonality and antibiotic-resistance genes among multiresistant Salmonella enterica serotype typhimurium phage-type U302 (MR U302) from humans, animals, and foods. | 2001 Spring |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/ampicillin.html
Ampicillin Dosage and Administration
This insert is for a Pharmacy Bulk Package and is intended for preparing IV admixtures only. Dosage recommendations for intramuscular or direct intravenous injection are for informational purposes only.
Infections of the respiratory tract and soft tissues.
Patients weighing 40 kg (88 lbs) or more: 250 to 500 mg every 6 hours.
Patients weighing less than 40 kg (88 lbs): 25 to 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals.
Infections of the gastrointestinal and genitourinary tracts (including those caused by Neisseria gonorrhoeae in females).
Patients weighing 40 kg (88 lbs) or more: 500 mg every 6 hours.
Patients weighing less than 40 kg (88 lbs): 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals.
In the treatment of chronic urinary tract and intestinal infections, frequent bacteriological and clinical appraisal is necessary. Smaller doses than those recommended above should not be used. Higher doses should be used for stubborn or severe infections. In stubborn infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy.
Urethritis in males due to N. gonorrhoeae.
Adults – Two doses of 500 mg each at an interval of 8 to 12 hours. Treatment may be repeated if necessary or extended if required.
In the treatment of complications of gonorrheal urethritis, such as prostatitis and epididymitis, prolonged and intensive therapy is recommended. Cases of gonorrhea with a suspected primary lesion of syphilis should have darkfield examinations before receiving treatment. In all other cases where concomitant syphilis is suspected, monthly serological tests should be made for a minimum of four months.
The doses for the preceding infections may be given by either the intramuscular or intravenous route. A change to oral Ampicillin may be made when appropriate.
Bacterial Meningitis
Adults and children – 150 to 200 mg/kg/day in equally divided doses every 3 to 4 hours. (Treatment may be initiated with intravenous drip therapy and continued with intramuscular injections.) The doses for other infections may be given by either the intravenous or intramuscular route.
Septicemia
Adults and children – 150 to 200 mg/kg/day. Start with intravenous administration for at least three days and continue with the intramuscular route every 3 to 4 hours.
Treatment of all infections should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. A minimum of 10-days treatment is recommended for any infection caused by Group A beta-hemolytic streptococci to help prevent the occurrence of acute rheumatic fever or acute glomerulonephritis.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14195635
Ampicillin was tested in vitro for antibacterial activity against 673 clinical isolates of Gram-negative bacilli and Streptococcus faecalis. Taking the group of 673 isolates tested as a whole, 448 (67 %) were inhibited by ampicillin at a concentration of 5 ug/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:02:54 GMT 2023
by
admin
on
Fri Dec 15 15:02:54 GMT 2023
|
Record UNII |
HXQ6A1N7R6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1500
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
||
|
CFR |
21 CFR 522.90A
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
||
|
CFR |
21 CFR 522.90B
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m1853
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
AMPICILLIN TRIHYDRATE
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless or almost odourless. Solubility: Slightly soluble in water; practically insoluble in ethanol (~750 g/l) TS and ether R. Category: Antibiotic. Storage: Ampicillin should be kept in a tightly closed container, protected from light. Labelling: The designation on the container of Ampicillin should state whether the substance is in the anhydrous form or is the trihydrate. Additional information: Even in the absence of light, Ampicillin is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Ampicillin contains not less than 95.0% and not more than 102.0% of C16H19N3O4S, calculated with reference to the anhydrous substance. | ||
|
1033407
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
7177-48-2
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
203115
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | RxNorm | ||
|
31209
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
DBSALT001206
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
C47960
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL174
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
HXQ6A1N7R6
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
SUB00509MIG
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
HXQ6A1N7R6
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
23565
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
100000092549
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
DTXSID9020083
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |